Cancerous disease modifying antibodies

Abstract

The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

1 . A method of extending survival and/or delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-5643 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and/or survival is extended. 
     
     
         2 . The method of  claim 1  wherein said antibody is conjugated to a cytotoxic moiety. 
     
     
         3 . The method of  claim 2  wherein said cytotoxic moiety is a radioactive isotope. 
     
     
         4 . The method of  claim 1  wherein said antibody activates complement. 
     
     
         5 . The method of  claim 1  wherein said antibody mediates antibody dependent cellular cytotoxicity. 
     
     
         6 . The method of  claim 1  wherein said antibody is a murine antibody. 
     
     
         7 . The method of  claim 1  wherein said antibody is a humanized antibody. 
     
     
         8 . The method of  claim 1  wherein said antibody is a chimerized antibody. 
     
     
         9 . An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as PTA-5643. 
     
     
         10 . The isolated antibody or antigen binding fragments of  claim 9 , wherein said isolated antibody or antigen binding fragments thereof is humanized. 
     
     
         11 . The isolated antibody or antigen binding fragments of  claim 9  conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells. 
     
     
         12 . The isolated antibody or antigen binding fragments of  claim 9 , wherein said isolated antibody or antigen binding fragments thereof is a chimerized antibody. 
     
     
         13 . The isolated antibody or antigen binding fragments of  claim 9 , wherein said isolated antibody or antigen binding fragments thereof is a murine antibody. 
     
     
         14 . The isolated clone deposited with the ATCC as PTA-5643. 
     
     
         15 . The method of  claim 1  wherein said tumor is a breast tumor. 
     
     
         16 . The method of  claim 1  wherein said tumor is an ovarian tumor.